ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 512

Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons

Yoichiro Haji1, Ryo Rokutanda2, Mitsumasa Kishimoto2 and Masato Okada2, 1Rheumatology, Daido Hospital, Nagoya, Japan, 2Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Anti-CCP antibodies and rheumatoid arthritis (RA), Diagnostic Tests

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate anti-cyclic citrullinated protein antibody positivity in the general population and to identify its prognosis.

Methods: Anti-cyclic citrullinated protein antibody (ACPA) were measured with immunochromatographic test in 3607 people who visited for routine annual medical check-up from November 2014 to March 2016. Four people with history of rheumatic diseases except for rheumatoid arthritis (RA) were excluded from analysis. For ACPA positive persons, consultation to rheumatology was recommended. They were examined ACPA with CLEIA method, anti-nuclear antibody test, and anti SS-A antibody test. Also rheumatologist performed detail physical examination. The classification criteria of 2010 ACR/EULAR were used for diagnosis of RA. Asymptomatic examinees with ACPA positive were recommended to visit every 6 months. Symptomatic examinees that did not fulfill classification criteria even if they have morning stiffness or joint pain were recommended to visit every 3 months. While follow-up period, an examinee that fulfills classification criteria was prescribed DMARDs in accordance with guidelines.

Results: ACPA positivity with immunochromatographic test was identified in 1.0% (n=37) of examinees. 51.4% were woman. There were no correlations between ACPA positivity and smoking, drinking, BMI, and history of cancer. Among ACPA positive examinees, 64%(n=24) consulted to rheumatology department. They were confirmed ACPA positivity with CLEIA method. 58.3% (n=14) were CLEIA method positive. 57.1% were woman. 4 examinees have already diagnosed as RA and 5 examinees have morning stiffness or joint pain, which did not fulfill classification criteria. Mean follow-up period of ACPA positive examinees with CLEIA and immunochromatographic method was 10.5 month. One of 5 symptomatic patients developed RA and she reached remission after 2 months after starting methotrexate.

Conclusion: Positivity of ACPA in general population was 1%. Regular follow-up of ACPA positive patients could lead prompt diagnosis and treatment.


Disclosure: Y. Haji, None; R. Rokutanda, None; M. Kishimoto, Eli Lilly and Company, 5; M. Okada, Santen Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, Abbott Japan, 8,Eli Lilly and Company, 5.

To cite this abstract in AMA style:

Haji Y, Rokutanda R, Kishimoto M, Okada M. Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anti-cyclic-citrullinated-protein-antibody-acpa-positivity-in-general-population-and-follow-up-results-for-acpa-positive-persons/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cyclic-citrullinated-protein-antibody-acpa-positivity-in-general-population-and-follow-up-results-for-acpa-positive-persons/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology